IVFNCT06191809
Evaluate the Effectiveness of Progestin-Primed Versus GnRH Antagonist Protocols in Vietnamese Women Undergoing In-vitro Fertilization
A study of IVF, run by Hanoi Medical University at 1 site in Vietnam.
Trial summary
This study aims to evaluate the efficacy of the progestin-primed ovary stimulation (PPOS) protocol compared to the standard GnRH antagonist (GnRH_ant) protocol across successive stages in a controlled ovarian stimulation (COS) and ICSI procedure. Read more about this study
- Who is it for?
- Ages 20 to 45 years, women only
- Conditions the study is for
- IVF
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 200 participants
- Where
- 1 siteVietnam
- Study dates
- 14 Feb 2023to 31 Dec 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 45 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Women meeting the sample selection criteria are as follows:
- Women age 20 to 45 years old.
- Infertility due to male factors, fallopian tube factors, or unknown causes.
- Undergoing IVF in one COS cycle and intended to apply either GnRH antagonist protocol or PPOS protocol
- Voluntary participation in research.
Who cannot join
- Any contraindications to ovarian stimulation and IVF/ICSI treatment
- Hyperprolactinemia or other endocrine diseases.
- Those who took hormone drugs within the past 3 months
- Suffering from systemic diseases such as kidney failure, lupus erythematosus, depression, etc.
- Abnormal structure of the uterine cavity.
- Patients with endometriosis or cancer
Show all 9Show fewer
- Random-start cycles.
- Oocyte donation cycles
- Perform embryo biopsy.
Trial locations and contacts
1 site in 1 country.
Vietnam1 site, 1 recruiting
- Recruiting
Univesity of Medicine and Pharmacy at Ho Chi Minh City
Ho Chi Minh City, 700000
Khue TT Le Thai Thanh, 0975585249, lethaithanhkhue@gmail.com
About this study
Official title: Evaluate the Effectiveness of Progestin-Primed Versus GnRH Antagonist Protocols in Vietnamese Women Undergoing In-vitro Fertilization: A Randomized Controlled Trial
This study aims to evaluate the efficacy of the progestin-primed ovary stimulation (PPOS) protocol compared to the standard GnRH antagonist (GnRH_ant) protocol across successive stages in a controlled ovarian stimulation (COS) and ICSI procedure.
Read the detailed description
Materials and Method
This was an open-label, randomized controlled trial conducted at the Assisted Reproduction Center of Tam Anh General Hospital. The study aimed to estimate the efficacy of the intervention (PPOS protocol) compared to a control group receiving a gonadotropin-releasing hormone (GnRH) antagonist protocol.
Sample size estimation
The sample size estimation procedure is detailed in the study protocol. In brief, the investigators conducted a simulation that implied the method by Cundill and Alexander (2015) with parameters derived from the clinical profile of 804 patients who underwent ovarian stimulation by two protocols at Tam Anh Hospital from January to October 2022. The procedure aimed to optimize non-inferiority testing on the difference in the quantity of retrieved oocytes between two groups, estimated by a Negative Binomial distribution. The simulation result indicated that a total sample size of 200 patients (n=100 for each treatment arm) would be required to achieve a statistical power of 0.8.
Recruitment of study participants
Infertile patients come for examination at the Assisted Reproduction Center of Tam Anh General Hospital, Hanoi, and the Assisted Reproduction and Graft Technology Center of Hanoi Medical University. In the basic infertility examination process at the hospital, the clinicians will consider the patient's inclusive and exclusive criteria. The clinicians will contact a research team member if the inclusive criteria are met. A research team member or hospital physician will invite the patient to participate, advise on the study procedure and the benefits and risks of participating, and answer any patient questions. If the patients agree to participate, they will consent to participate in the trial. Each participant will be randomly assigned to the treatment group using the PPOS protocol or the control group using the GnRH-ant regimen.
Treatment method
Ovarian stimulation protocols
Controlled ovarian hyperstimulation commenced on the second day of the menses utilizing recombinant follicle-stimulating hormone. In the gonadotropin-releasing hormone (GnRH) antagonist protocol group, pituitary suppression began on stimulation day six via daily 0.25 milligram GnRH antagonist administration (ganirelix or cetrorelix). In the progestin-primed ovarian stimulation (PPOS) group, 30mg/day of dydrogesterone was initiated on cycle day 2 through to trigger day.
Laboratory protocol
Oocyte-cumulus complexes were incubated for 2 hours in G-IVF medium (Vitrolife) using Origio benchtop incubators to complete nuclear maturation. After removing cumulus cells, denuded oocytes were evaluated under an inverted microscope to validate the achievement of metaphase II status, while degenerate, large, or severely dysmorphic oocytes were excluded. Intracytoplasmic sperm injection (ICSI) was executed 3-4 hours post-retrieval by experienced embryologists. Resultant zygotes were cultured in continuous single media (Fujifilm Irvine Scientific) within tri-gas incubators (37°C, 5% O2, 6% CO2) until day 3. Strict morphological criteria were enforced, only retaining normally fertilized two pronuclei zygotes while eliminating abnormal multinuclear embryos. Cleavage-stage quality was graded at 67-69 hours per Istanbul consensus based on cell number, fragmentation, multinucleation, and uniformity. On post-ICSI day 3, embryologists counseled patients on pursuing blastocyst culture versus cryopreservation. The morphology of the blastocysts was evaluated using the Gardner and Schoolcraft grading system, and embryos meeting the criteria of 3-6 AA/AB/BA blastocysts or 1-2 AA/AB embryos were classified as good quality.
- Conditions
- IVF
- Being tested
- Controlled Ovarian Stimulation Protocol
- Keywords
- ppos protocol
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Controlled Ovarian Stimulation ProtocolProcedure or surgery
Ovarian Stimulation Process:
- Stimulate ovaries with FSH \& hMG (150-375 IU) starting day 2-3 of menstruation.
- Monitor response with ultrasound \& hormones (E2, LH, P4).
- GnRH-ant arm: Prevent LH surge with Cetrorelix (0.25mg) starting day 5.
- PPOS arm: Suppress LH with Dydrogesterone (10mg x 3/day) from day 1.
- Trigger ovulation when ≥2 follicles >17mm (Triptorelin, hCG, or rhCG).
- Oocyte retrieval 36-38 hours later (>10mm follicles aspirated).
Embryo Culture \& Monitoring:
- Fertilize with ICSI.
- Culture \& evaluate embryos (43-45 hours, day 3/5).
- Freeze all embryos.
| Study group | Role | What they receive |
|---|---|---|
| PPOS protocol | Active comparator | Ovarian stimulation protocol used progestin as premature LH surge inhibitor Receives: Procedure: Controlled Ovarian Stimulation Protocol |
| GnRH-ant protocol | Active comparator | Ovarian stimulation protocol used GnRH antagonist as premature LH surge inhibitor Receives: Procedure: Controlled Ovarian Stimulation Protocol |
What is being measured
The primary outcome is the main question the study is designed to answer.
The quantity of day 3rd and day 5th embryos and MII oocytes
Measured: 11 months after initiation of treatment in either arm
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Jan 2024
- Study start14 Feb 2023
- Primary completion31 Dec 2024 (estimated)
- Study completion31 Dec 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for IVFStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hanoi Medical University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Thach Than Trong, Hanoi Medical University
- Investigators
- Thach Than Trong, Principal investigator, Hanoi Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06191809
- Sponsor's protocol ID
- 9720105
- Status last verified
- Jan 2024
- First submitted
- 16 Dec 2023
- Last updated
- 5 Jan 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Jan 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluate the Effectiveness of Progestin-Primed Versus GnRH Antagonist Protocols in Vietnamese Women Undergoing In-vitro Fertilization: A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT06191809
- Acronym / sponsor ID
- 9720105
- Conditions
- IVF
- Keywords
- ppos protocol
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Hanoi Medical UniversityUniversity, hospital or other
- Study start
- 14 Feb 2023 (actual)
- Primary completion
- 31 Dec 2024 (estimated)
- Study completion
- 31 Dec 2024 (estimated)
- First posted
- 5 Jan 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to evaluate the efficacy of the progestin-primed ovary stimulation (PPOS) protocol compared to the standard GnRH antagonist (GnRH_ant) protocol across successive stages in a controlled ovarian stimulation (COS) and ICSI procedure.
Detailed description
Materials and Method
This was an open-label, randomized controlled trial conducted at the Assisted Reproduction Center of Tam Anh General Hospital. The study aimed to estimate the efficacy of the intervention (PPOS protocol) compared to a control group receiving a gonadotropin-releasing hormone (GnRH) antagonist protocol.
Sample size estimation
The sample size estimation procedure is detailed in the study protocol. In brief, the investigators conducted a simulation that implied the method by Cundill and Alexander (2015) with parameters derived from the clinical profile of 804 patients who underwent ovarian stimulation by two protocols at Tam Anh Hospital from January to October 2022. The procedure aimed to optimize non-inferiority testing on the difference in the quantity of retrieved oocytes between two groups, estimated by a Negative Binomial distribution. The simulation result indicated that a total sample size of 200 patients (n=100 for each treatment arm) would be required to achieve a statistical power of 0.8.
Recruitment of study participants
Infertile patients come for examination at the Assisted Reproduction Center of Tam Anh General Hospital, Hanoi, and the Assisted Reproduction and Graft Technology Center of Hanoi Medical University. In the basic infertility examination process at the hospital, the clinicians will consider the patient's inclusive and exclusive criteria. The clinicians will contact a research team member if the inclusive criteria are met. A research team member or hospital physician will invite the patient to participate, advise on the study procedure and the benefits and risks of participating, and answer any patient questions. If the patients agree to participate, they will consent to participate in the trial. Each participant will be randomly assigned to the treatment group using the PPOS protocol or the control group using the GnRH-ant regimen.
Treatment method
Ovarian stimulation protocols
Controlled ovarian hyperstimulation commenced on the second day of the menses utilizing recombinant follicle-stimulating hormone. In the gonadotropin-releasing hormone (GnRH) antagonist protocol group, pituitary suppression began on stimulation day six via daily 0.25 milligram GnRH antagonist administration (ganirelix or cetrorelix). In the progestin-primed ovarian stimulation (PPOS) group, 30mg/day of dydrogesterone was initiated on cycle day 2 through to trigger day.
Laboratory protocol
Oocyte-cumulus complexes were incubated for 2 hours in G-IVF medium (Vitrolife) using Origio benchtop incubators to complete nuclear maturation. After removing cumulus cells, denuded oocytes were evaluated under an inverted microscope to validate the achievement of metaphase II status, while degenerate, large, or severely dysmorphic oocytes were excluded. Intracytoplasmic sperm injection (ICSI) was executed 3-4 hours post-retrieval by experienced embryologists. Resultant zygotes were cultured in continuous single media (Fujifilm Irvine Scientific) within tri-gas incubators (37°C, 5% O2, 6% CO2) until day 3. Strict morphological criteria were enforced, only retaining normally fertilized two pronuclei zygotes while eliminating abnormal multinuclear embryos. Cleavage-stage quality was graded at 67-69 hours per Istanbul consensus based on cell number, fragmentation, multinucleation, and uniformity. On post-ICSI day 3, embryologists counseled patients on pursuing blastocyst culture versus cryopreservation. The morphology of the blastocysts was evaluated using the Gardner and Schoolcraft grading system, and embryos meeting the criteria of 3-6 AA/AB/BA blastocysts or 1-2 AA/AB embryos were classified as good quality.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| PPOS protocol | Active comparator | Procedure: Controlled Ovarian Stimulation ProtocolOvarian stimulation protocol used progestin as premature LH surge inhibitor |
| GnRH-ant protocol | Active comparator | Procedure: Controlled Ovarian Stimulation ProtocolOvarian stimulation protocol used GnRH antagonist as premature LH surge inhibitor |
Who may qualify
- Ages
- 20 to 45 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Women age 20 to 45 years old.
- Infertility due to male factors, fallopian tube factors, or unknown causes.
- Undergoing IVF in one COS cycle and intended to apply either GnRH antagonist protocol or PPOS protocol
- Voluntary participation in research.
Key exclusion criteria (9 listed)
- Any contraindications to ovarian stimulation and IVF/ICSI treatment
- Hyperprolactinemia or other endocrine diseases.
- Those who took hormone drugs within the past 3 months
- Suffering from systemic diseases such as kidney failure, lupus erythematosus, depression, etc.
- Abnormal structure of the uterine cavity.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Controlled Ovarian Stimulation ProtocolOvarian Stimulation Process: * Stimulate ovaries with FSH \& hMG (150-375 IU) starting day 2-3 of menstruation. * Monitor response with ultrasound \& hormones (E2, LH, P4). * GnRH-ant arm: Prevent LH surge with Cetrorelix (0.25mg) starting day 5. * PPOS arm: Suppress LH with Dydrogesterone (10mg x 3/day) from day 1. * Trigger ovulation when ≥2 follicles >17mm (Triptorelin, hCG, or rhCG). * Oocyte retrieval 36-38 hours later (>10mm follicles aspirated). Embryo Culture \& Monitoring: * Fertilize with ICSI. * Culture \& evaluate embryos (43-45 hours, day 3/5). * Freeze all embryos. | Procedure or surgery | GnRH-ant protocol, PPOS protocol |
Primary outcome
The quantity of day 3rd and day 5th embryos and MII oocytes
Time frame: 11 months after initiation of treatment in either arm
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Jan 2024.
- Individual participant dataSharing planned: No
Related trials for IVF
RecruitingPhase 2
Ubiquinone vs. Ubiquinol Supplementation
IVF
Active, not recruitingPhase 1/2
Opt-IVF for Personalized Medicine for Normal Responders
Ivf
Enrolling by invitation
Investigation of the Treatment of Patients With Mitochondrial Defects by Assisted Reproductive Technology
Pearson Syndrome, Mitochondria DNA Deletion
Recruiting
Dietary Intervention to Improve Fertility in Women With Endometriosis Undergoing IVF
Endometriosis
Recruiting
Trigger Timing in Ovarian Stimulations
IVF Outcome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Thach Than Trong principal investigator
Hanoi Medical University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study of IVF, run by Hanoi Medical University at 1 site in Vietnam.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 5 Jan 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Vietnam. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Thach Than Trong (+84908400040, thachthan007@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The quantity of day 3rd and day 5th embryos and MII oocytes (time frame: 11 months after initiation of treatment in either arm). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jan 2024.